Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 2
2008 1
2009 3
2010 3
2011 2
2012 3
2013 1
2014 2
2015 1
2016 1
2019 1
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

17 results
Results by year
Filters applied: . Clear all
Page 1
Evaluation of antihypertensive drugs in combination with enzyme replacement therapy in mice with Pompe disease.
Han SO, Haynes AC, Li S, Abraham DM, Kishnani PS, Steet R, Koeberl DD. Han SO, et al. Mol Genet Metab. 2020 Feb;129(2):73-79. doi: 10.1016/j.ymgme.2019.10.005. Epub 2019 Oct 17. Mol Genet Metab. 2020. PMID: 31645300
Immunomodulatory gene therapy in lysosomal storage disorders.
Koeberl DD, Kishnani PS. Koeberl DD, et al. Curr Gene Ther. 2009 Dec;9(6):503-10. doi: 10.2174/156652309790031094. Curr Gene Ther. 2009. PMID: 19807648 Free PMC article. Review.
Glycogen storage disease types I and II: treatment updates.
Koeberl DD, Kishnani PS, Chen YT. Koeberl DD, et al. J Inherit Metab Dis. 2007 Apr;30(2):159-64. doi: 10.1007/s10545-007-0519-9. Epub 2007 Feb 16. J Inherit Metab Dis. 2007. PMID: 17308886 Free PMC article. Review.
A beta-blocker, propranolol, decreases the efficacy from enzyme replacement therapy in Pompe disease.
Han SO, Pope R, Li S, Kishnani PS, Steet R, Koeberl DD. Han SO, et al. Mol Genet Metab. 2016 Feb;117(2):114-9. doi: 10.1016/j.ymgme.2015.09.012. Epub 2015 Oct 3. Mol Genet Metab. 2016. PMID: 26454691 Free PMC article.
Adjunctive β2-agonists reverse neuromuscular involvement in murine Pompe disease.
Li S, Sun B, Nilsson MI, Bird A, Tarnopolsky MA, Thurberg BL, Bali D, Koeberl DD. Li S, et al. FASEB J. 2013 Jan;27(1):34-44. doi: 10.1096/fj.12-207472. Epub 2012 Sep 19. FASEB J. 2013. PMID: 22993195 Free PMC article.
Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease.
Zhang P, Sun B, Osada T, Rodriguiz R, Yang XY, Luo X, Kemper AR, Clay TM, Koeberl DD. Zhang P, et al. Hum Gene Ther. 2012 May;23(5):460-72. doi: 10.1089/hum.2011.063. Epub 2012 Mar 29. Hum Gene Ther. 2012. PMID: 22260439 Free PMC article.
Adjunctive β2-agonist treatment reduces glycogen independently of receptor-mediated acid α-glucosidase uptake in the limb muscles of mice with Pompe disease.
Farah BL, Madden L, Li S, Nance S, Bird A, Bursac N, Yen PM, Young SP, Koeberl DD. Farah BL, et al. FASEB J. 2014 May;28(5):2272-80. doi: 10.1096/fj.13-244202. Epub 2014 Jan 21. FASEB J. 2014. PMID: 24448824 Free PMC article.
Assessment of toxicity and biodistribution of recombinant AAV8 vector-mediated immunomodulatory gene therapy in mice with Pompe disease.
Wang G, Young SP, Bali D, Hutt J, Li S, Benson J, Koeberl DD. Wang G, et al. Mol Ther Methods Clin Dev. 2014 Jun 11;1:14018. doi: 10.1038/mtm.2014.18. eCollection 2014. Mol Ther Methods Clin Dev. 2014. PMID: 26015962 Free PMC article.
β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease.
Koeberl DD, Li S, Dai J, Thurberg BL, Bali D, Kishnani PS. Koeberl DD, et al. Mol Genet Metab. 2012 Feb;105(2):221-7. doi: 10.1016/j.ymgme.2011.11.005. Epub 2011 Nov 11. Mol Genet Metab. 2012. PMID: 22154081 Free PMC article.
Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle.
Koeberl DD, Luo X, Sun B, McVie-Wylie A, Dai J, Li S, Banugaria SG, Chen YT, Bali DS. Koeberl DD, et al. Mol Genet Metab. 2011 Jun;103(2):107-12. doi: 10.1016/j.ymgme.2011.02.006. Epub 2011 Feb 13. Mol Genet Metab. 2011. PMID: 21397538 Free PMC article.
17 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page